TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid
Status:
Completed
Trial end date:
2021-01-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of treatment with azacitidine (an FDA
approved drug for the treatment of MDS) and high dose ascorbic acid in patients with TET2
mutations. This approach is intended to enhance the enzymatic activity of TET2 protein, which
in term may help to improve counts and symptoms, related to Myelodysplastic Syndromes and
Acute Myeloid Leukemia. This combination is specific to individuals who carry this mutation.